Antibody–drug conjugates have emerged as a powerful tool to deliver highly targeted cancer therapies. Next-generation antibody-drug conjugate designs aim to push the envelope even further.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback